Atracurium Besylate Injection, Solution
Product Images NDC 0409-1105

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Atracurium Besylate (NDC 0409-1105). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula Atracurium Besylate (Atracurium 01)

Chemical structure diagram of Atracurium Besylate, showing its molecular components including aromatic rings, methoxy groups, quaternary nitrogen atoms, ester linkages, and besylate counterions as depicted in the image.*

FDA Label Image

Principal Display Panel (10 mL Vial Label)

FDA Label Image

Principal Display Panel (10 mL Vial Carton)

Atracurium Besylate Injection USP 100 mg/10 mL (10 mg/mL) in a 10 mL multiple dose vial. The label includes warnings about its paralytic effects and instructions for refrigeration at 2°C to 8°C, with protection from freezing and light. Manufactured by Gland Pharma Limited and labeled for Hospira, Inc.*

FDA Label Image

Principal Display Panel (5 mL Vial Label)

Atracurium Besylate Injection USP 100 mg/10 mL (10 mg/mL) intravenous injection solution label, manufactured by Gland Pharma Limited for Hospira, Inc. The package contains 10 x 10 mL multiple-dose vials. The label includes warnings for the drug as a paralyzing agent and storage instructions specifying refrigeration at 2°C to 8°C (36°F to 46°F), protection from light, and not freezing.*

FDA Label Image

Principal Display Panel (5 mL Vial Carton)

Label for Atracurium Besylate Injection USP, 50 mg per 5 mL (10 mg/mL) single dose vial. It is a sterile, non-pyrogenic solution for intravenous injection. The label includes a warning that it is a paralyzing agent requiring immediate availability of artificial respiration. Manufactured by Hospira, Inc. The vial volume is 5 mL.*

FDA Label Image

Atracurium 06

Atracurium Besylate Injection USP 50 mg/5 mL (10 mg/mL) is presented in a carton containing 10 single-dose vials of 5 mL each. The label highlights its use for intravenous injection and indicates it is a sterile, non-pyrogenic paralyzing agent. Manufactured by Gland Pharma Limited for Hospira, Inc., the packaging includes storage instructions and a warning about respiratory arrest.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.